You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《盈利預喜》聯康生物科技(00690.HK)料年度虧轉盈 賺最少3,600萬元
阿思達克 03-06 16:35
聯康生物科技(00690.HK)預計,截至去年12月31日止年度純利不低於3,600萬元,2021年同期則為虧損1,960萬元 。 公司指,預期增長主要歸因於各管線產品銷售持續增長,其中在國家集採、地區聯盟集採政策推動下、公司中選產品逐步增加終端醫院的覆蓋,抗菌及糖尿病領域相關藥品增幅較大,帶動主營業績增長;及研發項目中治療骨質疏鬆的一款PTH水針項目,自去年7月開始進入生物等效性試驗階段,自此相關研發費用符合會計資本化的要求,計入資本化金額1,749萬元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account